title: Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.
abstract: Autologous stem cell transplantation (ASCT) is considered the gold standard in the frontline therapy of younger patients with multiple myeloma because it results in higher complete remission (CR) rates and longer event-free survival than conventional chemotherapy. The greatest benefit from ASCT is obtained in patients achieving CR after transplantation, the likelihood of CR being associated with the M-protein size at the time of transplantation. The incorporation of novel agents results in higher pre- and posttransplantation CR rates. Induction with bortezomib-containing regimens is encouraging in patients with poor-risk cytogenetics. However, longer follow-up is required to assess the impact of this increased CR on long-term survival. The results of posttransplantation consolidation/maintenance with new drugs are encouraging. All this indicates that, in the era of novel agents, high-dose therapy should be optimized rather than replaced. Because of its high transplantation-related mortality, myeloablative allografting has been generally replaced by reduced-intensity conditioning (reduced intensity conditioning allogeneic transplantation). The best results are achieved after a debulky ASCT, with a progression-free survival plateau of 25% to 30% beyond 6 years from reduced intensity conditioning allogeneic transplantation. The development of novel reduced-intensity preparative regimens and peri- and posttransplantation strategies aimed at minimizing graft-versus-host disease, and enhancing the graft-versus-myeloma effect are key issues.
authors.affiliation: Department of Hematology and Bone Marrow Transplant Unit, Institut of Hematology and Oncology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. jblade@clinic.ub.es
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
authors.forename: Laura
authors.initials: L
authors.lastname: Rosiñol
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Cibeira
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.forename: Enric
authors.initials: E
authors.lastname: Carreras
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D016896:Treatment Outcome